Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"

Background. In Russia, as well as throughout the world, the use of glucocorticoids (GC) in the treatment of rheumatoid arthritis (RA) is widespread, often going beyond the recommendations for both duration and dose regimen, which makes it relevant to study the long-term consequences of such a wrong...

Full description

Bibliographic Details
Main Authors: Andrey V. Gordeev, Elena V. Matyanova, Elena A. Galushko
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2023-07-01
Series:Терапевтический архив
Subjects:
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/551819/132626
_version_ 1797772965471846400
author Andrey V. Gordeev
Elena V. Matyanova
Elena A. Galushko
author_facet Andrey V. Gordeev
Elena V. Matyanova
Elena A. Galushko
author_sort Andrey V. Gordeev
collection DOAJ
description Background. In Russia, as well as throughout the world, the use of glucocorticoids (GC) in the treatment of rheumatoid arthritis (RA) is widespread, often going beyond the recommendations for both duration and dose regimen, which makes it relevant to study the long-term consequences of such a wrong (EULAR, 2022) use of GC in RA therapy. Materials and methods. Of 1143 patients with active RA (ACR/EULAR 2010), two groups were formed: A (n=782) RA patients with more than 6 months of experience with systemic GC; group B (n=245) no experience of taking GC. The cumulative disease index (CIRS) was used to assess the comorbidity profile. Results. Patients in group A were older (p0.0001), with a longer duration of RA (p=0.0004) and more often with IV radiological stage (p=0.02). With comparable (DAS28) RA activity, the D2T variant of RA was more often detected in them (p=0.036). RA therapy in group A was characterized by a large number of used disease-modifying anti-rheumatic drugs (p=0.0003), more frequent development of methotrexate-induced hepatitis (p=0.03). In group A, the time interval between the onset of RA and the initiation of biological therapy was longer (p=0.0001) and directly correlated with the duration of GC therapy (Rs=0.38) with a comparable qualitative structure of the used b/tsDMARDs. In the same group, tuberculosis, hypertension, chronic kidney disease, cataract and osteoporosis (p0.05) and its complications were diagnosed significantly more often with a comparable frequency of cardiovascular disease, diabetes, and gastrointestinal lesions. In group A, a higher CIRS multimorbidity index was detected, and the CIRS severity index was lower than in group B (p0.05). Conclusion. Long-term use of GC did not lead to a decrease in disease activity, inhibition of radiographic progression, delayed the timely administration of b/tsDMARDS and was accompanied by an increase in the multimorbid load.
first_indexed 2024-03-12T21:59:26Z
format Article
id doaj.art-d19ed0da1499460d8875e4c13173b267
institution Directory Open Access Journal
issn 0040-3660
2309-5342
language Russian
last_indexed 2024-03-12T21:59:26Z
publishDate 2023-07-01
publisher "Consilium Medicum" Publishing house
record_format Article
series Терапевтический архив
spelling doaj.art-d19ed0da1499460d8875e4c13173b2672023-07-25T11:14:52Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422023-07-0195538038510.26442/00403660.2023.05.20219678291Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"Andrey V. Gordeev0https://orcid.org/0000-0001-9820-8851Elena V. Matyanova1https://orcid.org/0000-0003-2135-5524Elena A. Galushko2Nasonova Research Institute of RheumatologyNasonova Research Institute of RheumatologyNasonova Research Institute of RheumatologyBackground. In Russia, as well as throughout the world, the use of glucocorticoids (GC) in the treatment of rheumatoid arthritis (RA) is widespread, often going beyond the recommendations for both duration and dose regimen, which makes it relevant to study the long-term consequences of such a wrong (EULAR, 2022) use of GC in RA therapy. Materials and methods. Of 1143 patients with active RA (ACR/EULAR 2010), two groups were formed: A (n=782) RA patients with more than 6 months of experience with systemic GC; group B (n=245) no experience of taking GC. The cumulative disease index (CIRS) was used to assess the comorbidity profile. Results. Patients in group A were older (p0.0001), with a longer duration of RA (p=0.0004) and more often with IV radiological stage (p=0.02). With comparable (DAS28) RA activity, the D2T variant of RA was more often detected in them (p=0.036). RA therapy in group A was characterized by a large number of used disease-modifying anti-rheumatic drugs (p=0.0003), more frequent development of methotrexate-induced hepatitis (p=0.03). In group A, the time interval between the onset of RA and the initiation of biological therapy was longer (p=0.0001) and directly correlated with the duration of GC therapy (Rs=0.38) with a comparable qualitative structure of the used b/tsDMARDs. In the same group, tuberculosis, hypertension, chronic kidney disease, cataract and osteoporosis (p0.05) and its complications were diagnosed significantly more often with a comparable frequency of cardiovascular disease, diabetes, and gastrointestinal lesions. In group A, a higher CIRS multimorbidity index was detected, and the CIRS severity index was lower than in group B (p0.05). Conclusion. Long-term use of GC did not lead to a decrease in disease activity, inhibition of radiographic progression, delayed the timely administration of b/tsDMARDS and was accompanied by an increase in the multimorbid load.https://ter-arkhiv.ru/0040-3660/article/viewFile/551819/132626rheumatoid arthritisglucocorticoidsmultimorbidityadverse reactions
spellingShingle Andrey V. Gordeev
Elena V. Matyanova
Elena A. Galushko
Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"
Терапевтический архив
rheumatoid arthritis
glucocorticoids
multimorbidity
adverse reactions
title Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"
title_full Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"
title_fullStr Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"
title_full_unstemmed Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"
title_short Long-term use of glucocorticoids in patients with active rheumatoid arthritis: therapeutic "freeze frame"
title_sort long term use of glucocorticoids in patients with active rheumatoid arthritis therapeutic freeze frame
topic rheumatoid arthritis
glucocorticoids
multimorbidity
adverse reactions
url https://ter-arkhiv.ru/0040-3660/article/viewFile/551819/132626
work_keys_str_mv AT andreyvgordeev longtermuseofglucocorticoidsinpatientswithactiverheumatoidarthritistherapeuticfreezeframe
AT elenavmatyanova longtermuseofglucocorticoidsinpatientswithactiverheumatoidarthritistherapeuticfreezeframe
AT elenaagalushko longtermuseofglucocorticoidsinpatientswithactiverheumatoidarthritistherapeuticfreezeframe